Table 3 Incidence of treatment-emergent adverse eventsa
From: Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial
Incidence, n(%) | Placebo (n= 50) | Milnacipran (n= 100) |
|---|---|---|
Patients with ≥1 TEAE | 29 (58) | 47 (47) |
Nausea | 1 (2) | 4 (4) |
Headache | 0 | 4 (4) |
Vomiting | 1 (2) | 4 (4) |
Sinusitis | 3 (6) | 4 (4) |
Upper respiratory tract infection | 2 (4) | 4 (4) |
Fatigue | 1 (2) | 4 (4) |
Pain in extremity | 1 (2) | 4 (4) |
Fall | 0 | 4 (4) |
Arthralgia | 1 (2) | 3 (3) |
Fibromyalgia | 1 (2) | 3 (3) |
Peripheral edema | 3 (6) | 2 (2) |
Hypothyroidism | 2 (4) | 1 (1) |
Influenza | 2 (4) | 1 (1) |
Irritability | 3 (6) | 0 |
Neck pain | 2 (4) | 0 |